Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ETBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea ...

Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodiumSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics ...

Atea Pharmaceuticals (AVIR) announced the presentation of new modeling data predicting that the Company’s combination regimen of bemnifosbuvir, ...

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...

Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups –– In addition to ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS’’ or the 'Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ...

Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential. On October 22, Nektar ...

HanchorBio Inc., today announced that the preclinical data on HCB301, has been accepted for presentation at the 40th Annual ...

MRT-8102 is a selective, potent, and durable NEK7 degrader. Activation of the NLRP3 inflammasome critically depends on NEK7. Administration of MRT-8102 led to inhibition of NLRP3 inflammasome in vitro ...